Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2020 Net Income$1.87B$1.87BN/M vs Q1 2020 EPS Diluted$26.95$26.95N/M vs Q1 2020 Operating Income-$91,217,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$121,761,000N/M ended Mar 31, 2021 · filed Apr 29, 2021 · 29 d after period end